milliporesigma videos

31. Partner With A CDMO For Your Biologic Commercial-Scale Manufacturing 3/18/2022

    Discover how our full-service biologics CDMO can help you navigate the journey from clinical to commercial drug substance manufacturing and provide tailored guidance and solutions.

32. Combining Expertise With Best-In-Class Technology 10/20/2021

    Members of the MilliporeSigma leadership team reflect on the longstanding experience of our BioReliance® viral vector manufacturing facilities. Our legacy experience, alongside our brand new facility and latest industry innovations, ensure we are a preferred partner to pioneer the path to cures.

33. How MilliporeSigma Promotes Quality And Risk Reduction 10/20/2021

    Learn how MilliporeSigma’s new facility was built with quality and risk reduction at the top of mind and its experts have the experience to support large-scale programs through commercialization.

34. MilliporeSigma Large Scale Capabilities Tour 10/20/2021

    A detailed look at MilliporeSigma’s new BioReliance® viral vector manufacturing facility and how we have employed the latest innovations and quality systems to deliver best-in-class gene therapy services.

35. The Blazar® Platform In A Minute 3/12/2021

    The Blazar® Rodent Panel from the BioReliance® portfolio can speed cell line characterization and bulk harvest lot release testing. This degenerate PCR-based method accelerates characterization by reducing timelines by up to 80% and replaces the use of animals.

36. Level Up With Product Characterization 3/12/2021

    In the race to bring a new biotherapeutic to market, unexpected obstacles can slow you down or even knock you back a few steps. But with the right information at the right time, and an experienced partner to provide scientific, regulatory, and bioprocessing guidance and support, you can find a smoother, faster path to the finish line.

37. CHO Fed-batch Portfolio: Cellvento® And EX-CELL® Advanced Media And Feeds 3/11/2021

    Cellvento® and EX-CELL® Advanced cell culture media supports consistent growth and performance from development to production. Get the enhanced performance, assured regulatory compliance and the security of supply necessary in today’s biopharmaceutical environment.

38. Bio4C ProcessPad™ Product Overview 5/19/2020

    Introducing Bio4C ProcessPad™ Software, part of the BioContinuum™ Platform.

39. Reduce The Level Of Host Cell Protein In The Bioreactor Harvest 12/11/2019

    Host cell proteins (HCPs) are an inevitable byproduct of biologics manufacturing and can have an impact on product quality and efficacy as well as patient safety. Processes designed to remove HCPs from the bioreactor harvest must not only be successful in achieving acceptable limits, but also be scalable. Learn how we helped our client reduce the level of HCPs in the bioreactor harvest prior to a production run to supply drug substance for a scheduled Phase 1 clinical trial in a very tight timeline.

40. Optimize The Formulation Of A Monoclonal Antibody 12/11/2019

    You have a molecule of interest and need an effective formulation to maximize stability and minimize aggregation. As with all formulations, it is essential that the buffers and excipients ensure stability of the drug substance, be compatible with each other and meet regulatory requirements. An emerging biotech company sought our help in developing a formulation for a monoclonal antibody. Learn how we have delivered an optimized formulation for this customer in three months.